Help patients explore everything CAR T Cell Therapy

Posted on 11/12/2025

A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit www.explorecelltherapy.com or download the resource below to learn more.

View Resource

Patient Out-of-Pocket (OOP) Costs for Covered Medicare Part D Drugs will be Capped in 2026

Posted on 11/12/2025

The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3

• In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.
• Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.

View Resource to Learn More

CONSIDERATIONS FOR NEOADJUVANT AND ADJUVANT THERAPY

Posted on 11/12/2025

In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.

View Resource

Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma

Posted on 11/6/2025

To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.

View Resource

Pfizer Oncology Together

Posted on 10/29/2025

Live: Call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET)

Online: Visit http://PfizerOncologyTogether.com

Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges. 

Pfizer Oncology Together can help healthcare providers by: 

• Assisting with benefits verification, prior authorizations, appeals, billing and coding, and specialty pharmacy coordination 
• Connecting them and their office staff to a Pfizer Field Reimbursement Manager (FRD) who can help address specific access and reimbursement issues—in person or over the phone  
• Offering and assisting with online portals that provide registered users with access and financial assistance resources 

Pfizer Oncology Together can help patients by: 

• Connecting them with financial assistance resources—regardless of their insurance coverage 
• Providing personalized support from a Pfizer Oncology FRM who can help identify resources and organizations that may provide additional assistance  

Please visit http://PfizerOncologyTogether.com for more details, or contact your local FRM or AP&R Director to learn more.

© 2024 Pfizer Inc. All rights reserved. PP-UNP-USA-4653 September 2024

Pfizer | MyHealthcareFinances

Posted on 10/29/2025

MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit https://www.myhealthcarefinances.com/ for more information.

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Posted on 10/22/2025

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.  

More info: Study Details | Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | ClinicalTrials.gov.   Or visit elegantstudy.com and/or scan QR code below:

Explore emerging real-world evidence in front-line BPDCN

Posted on 09/17/202

This new publication explores real-world safety and efficacy in patients treated with a CD123 targeted therapy in newly diagnosed blastic plasmacytoid dendritic cell neoplasms.

View Resource

A Children’s Book for Families with MBC

Posted on 09/11/2025

Living with metastatic breast cancer and looking for more whole-family support? Get a discussion guide for The Adventure Jar, printouts to make own of your own, and more at Support for Families.

Learn More

OPDIVO Qvantig™ permanent J-code available as of July 1, 2025

Posted on 08/20/2025

CMS has granted a unique J-code, J9289, for the use of OPDIVO Qvantig™ across all outpatient settings. J9289 is effective for dates of service on or after July 1, 2025. Bristol Myers Squibb would appreciate your partnership in updating systems and locations involved with the HCPCS and NDC information for J9289..

Learn More